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In a number of cardiac conditions (acute myocardial
infarction, chronic left ventricular aneurysm, dilated
cardiomyopathy, infective endocarditis and atrial fi-
brillation in the absence of valvular disease), the risk of
embolism gives cause for concern. Although anticoag-
ulation with warfarin (Coumadin)-derivatives has been
shown to be effective in some of these situations, there
is no evidence regarding the role of antiplatelet agents.
The common factor in the thromboembolic potential
of acute myocardial infarction, chronic left ventricular
aneurysm and dilated cardiomyopathy is mural throm·
bus. This can be detected by two-dimensional echocardi·
ography and indium-Ill platelet scintigraphy. Although
of value in elucidating the natural history of mural
thrombus, in most cases, management is not substan-
tially aided by these investigations.
In patients with extensive myocardial infarction, par-
ticularly anterior infarction, moderate intensity anti-
coagulation started soon after hospital admission reduces
the rate of embolism. After 8 to 12 weeks, embolic risk
is low so that anticoagulants can usually be discontinued.
Patients with chronic left ventricular aneurysm have a
low incidence of embolism; anticoagulation is, therefore,
inappropriate. Dilated cardiomyopathy is associated with
a high risk of embolism; moderate intensity anticoagu-
lation may be advisable in many such cases. Little in-
formation is available regarding the incidence of throm-
boembolism or the role of antithrombotic therapy in the
patient with a diffusely dilated left ventricle due to isch-
emic heart disease.
In native valve infective endocarditis, the risk of hem-
In this presentation, we will discuss intracavitary thrombosis
and consequent embolism in patients with acute myocardial
infarction, chronic left ventricular aneurysm, dilated car-
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orrhage is high, and the efficacy of conventional anti-
coagulants unclear; thus, anticoagulation should not be
instituted for the cardiac condition as such. However,
in prosthetic valve endocarditis, the risk of embolism
seems to be very high, and anticoagulant therapy should
be continued, but with great care because there is a
substantial risk of cerebral hemorrhage.
Atrial fibrillation in patients with valvular heart dis-
ease is dealt with in a previous review. Patients with
nonvalvular atrial fibrillation are at varying risk of em-
bolism, depending on the etiology of the arrhythmia;
trials of antithrombotic therapy are needed for the var-
ious subsets of patients. In most elderly patients, the
etiology is not known, and their stroke risk is high. The
risk of embolism in younger patients with idiopathic
atrial fibrillation is so low as to make any antithrombotic
therapy unnecessary. Patients with atrial fibrillation due
to hypertrophic cardiomyopathy are at a high risk of
embolism, while for patients with atrial fibrillation due
to ischemic heart disease, the risk is uncertain. Anti-
coagulation is appropriate in some patients around the
time of direct current cardioversion. In addition, in those
conditions that would of themselves merit long-term an·
ticoagulation, this should be continued after cardio-
version.
For each patient, the potential benefits of anticoag-
ulation have to be carefully balanced against the risks
of bleeding. The intensity of anticoagulant therapy ap-
plied should be matched to the patient's clinical condi-
tion.
(J Am Coil CardioI1986;8:76B-87B)
diomyopathy. infective endocarditis and atrial fibrillation.
Embolism makes an important contribution to the morbidity
and mortality associated with each of these conditions, but
there is considerable controversy regarding their optimal
antithrombotic management because few large randomized
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studies have addressed this issue, Our analysis aims to de-
scribe the impact of thromboembolism and define the po-
tential risks and benefits of anticoagulation in this group of
conditions, We offer guidelines for therapy on the basis of
our own clinical practice and the recommendations of the
American College of Chest Physicians (ACCP)-National
Heart, Lung, and Blood Institute Committee (1),
Mural Thrombi
Intraventricular mural thrombi are common in patients
with acute myocardial infarction, chronic left ventricular
aneurysm and dilated cardiomyopathy, The improvements
in imaging of thrombi by both two-dimensional echocardi-
ography and scintigraphy with indium-labeled platelets has
led to increased interest in the detection of mural thrombi.
with several reviews (2-7) appearing over the last few years,
Underlying pathology. Two major mechanisms con-
tribute to intracavitary thrombus formation in patients with
acute myocardial infarction, chronic left ventricular aneu-
rysm and dilated cardiomyopathy, namely, abnormalities of
the endocardium and stasis, In the first 2 days after myo-
cardial infarction, leukocytic infiltration lifts off the endo-
cardium (8), exposing subendothelial tissue. Consequently,
the circulating blood is exposed to a thrombogenic surface,
and thrombi become common by 4 to 5 days after infarction
(9), If a left ventricular aneurysm develops, endocardial
abnormalities persist and may be fibroelastic or thrombotic
(10), The latter is more likely to be the source of emboli,
Endocardial abnormalities may also be seen in patients with
cardiomyopathy (11).
Thrombi developing in patients with myocardial infarc-
tion are always adherent to regions of akinesia or dyskinesia
(12), with stasis of adjacent blood. Stasis of intracavitary
blood within some left ventricular aneurysms can be de-
tected by the demonstration of swirling smoke-like echoes
by two-dimensional echocardiography (13,14). Stasis in the
atria in patients with atrial fibrillation predisposes to throm-
bus formation in a similar way.
In patients with myocardial infarction, a third factor, the
systemic reaction to the event, with fever, leukocytosis and
increased plasma concentrations of acute phase proteins,
may also contribute to the tendency to form thrombi (15),
Imaging techniques for the detection of mural throm-
bus. Angiography may detect left ventricular thrombus.
However, it is not suited for repeated observations and is
insensitive, detecting only about 30% of pathologically con-
firmed mural thrombi (16,17). In addition, angiography in
patients with left ventricular aneurysm may fail to detect
thrombus because the apex may not be well filled during
left ventriculography, and the thrombus often conforms to
the outline of the rest of the ventricle, Computed tomog-
raphy and nuclear magnetic resonance imaging have been
used to detect mural thrombus and are promising techniques.
Two-dimensional echocardiography has been applied to
the detection of mural thrombi in the three left ventricular
conditions under consideration (18,19) (Fig. 1). Adequate
images are obtained in most patients (19), and the technique
is suitable for repeated observations. Correct interpretation
of intracavitary echoes as thrombus is clearly essential.
Thrombi are almost always associated with an abnormality
of wall motion (12), commonly at the apex. The margins
of the thrombus are distinct, with occasionally free motion
of protruding parts of the mass. The texture of the mass is
usually different from that of the underlying myocardium.
The mass may vary in appearance in serial examinations.
In some cases, the center of the thrombus is lucent (19,20),
a feature seen shortly before the thrombus becomes unde-
tectable, and thought to be due to spontaneous lysis (19).
Sources of difficulty may include apical trabeculation in
patients with left ventricular hypertrophy, false chordae and
tangential imaging of normal left ventricular myocardium
(21). Near field artifact is a particular problem when imaging
from the apex, especially in the presence of increased myo-
cardial echogenicity (20), Despite these problems, studies
(18,20,22) of the performance of echocardiography suggest
a sensitivity and specificity of 80 to 90% or greater.
Scintigraphy after the administration of indium-ill-la-
beled platelets, unlike two-dimensional echocardiography,
provides pathophysiologic data by detecting continuing dep-
osition of platelets on the thrombus (18). Images have to
be obtained soon after injection and later after time has
elapsed to allow platelets to accumulate on the thrombus,
typically 3 to 4 days. Only those thrombi actively incor-
porating platelets are imaged. Because of this, the technique
has a sensitivity of only about 70%, although false positive
studies are unusual (6,23). It is not known whether contin-
uing platelet incorporation into the thrombus, as detected
by indium-labeled platelet scintigraphy, is a marker for greater
embolic potential when compared with the echocardio-
graphic detection of thrombus that does not take up platelets
actively,
Both two-dimensional echocardiography and indium-la-
beled platelet scintigraphy are reliable and efficient tech-
niques and have furthered our understanding of the fre-
quency and significance of mural thrombi. However, their
value to the clinician in the management of the individual
patient is not well defined. We believe that the results of
these tests have only limited value in therapeutic decision
making.
Mural Thrombosis and Thromboembolism in
Specific Clinical Settings
Acute Myocardial Infarction
Myocardial infarction predisposes to both mural throm-
bus formation and subsequent embolism. Only a small pro-
portion of patients with myocardial infarction and mural
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thrombus will develop clinical embolism, although most
patients with clinical arterial embolism have or have had
mural thrombus. We, therefore, consider both mural throm-
bus formation, detected pathologically and by the imaging
techniques discussed, and embolism detected clinically.
Natural history and risk factors. Autopsy studies (24,25)
suggest that about 40% (range 17 to 66) of patients dying
after myocardial infarction have mural thrombus at the time
of death. This figure may overestimate the actual frequency
in life because it includes patients with larger infarcts (those
who died) and patients with infarcts of various ages.
Mural thrombus detection. Echocardiography frequently
reveals mural thrombus in patients with acute myocardial
Figure l. Mural thrombus detected by echocardiography. Upper
panel, Thrombus (T) protruding into the left ventricular cavity in
this apical four chamber view. Lower panel, Multilobular. pe-
dunculated thrombus (TH), in a patient with a dyskinetic apex due
to recent infarction, again in an apical four chamber view. (Lower
panel reprinted with permission from Goldman ME, Friedman S.
Introduction to Cross-sectional Echocardiography. an AV Pro-
gram. Medical Education Programs Ltd, 1984.)
infarction (Fig. I). Most echocardiographic studies show an
incidence rate of 30 to 40% in patients with anterior in-
farction, and up to 5% in patients with inferior myocardial
infarction. The thrombi are seen most frequently on the third
to sixth days after the infarction. Asinger et a1. (12) reported
the results of echocardiography in 70 patients with a first
infarction studied prospectively, in whom echocardiograms
were performed at intervals of approximately 3 days. De-
spite the adminstration of low dose anticoagulants, 12 of
35 patients with anterior infarction developed mural throm-
bus compared with none of 35 patients with inferior in-
farction. Thrombi were first detected between I and 11
(mean 5) days after infarction. A similar study (26) of 54
patients with anterior infarction revealed mural thrombus in
17 (31 %) in the absence of anticoagulation. More detail of
the natural history was provided by a study (27) of 96
patients treated with heparin 10,000 IU/day subcutaneously,
with additional warfarin for patients with anterior infarction.
These patients were imaged within 24 hours of infarction
and at 3 days, 4 days and 4 months. A total of 18 patients
developed thrombus. Two thrombi were present within 24
hours of admission, a further 3 by 2 days and a further 10
by 3 days. Three additional patients had developed thrombus
by the 4 month examination. In all three studies, thrombus
was much more frequent in patients with a large anterior
wall infarct, particularly those with apical dyskinesia. How-
ever, mural thrombus has been detected in 30% of patients
with inferior infarction in one series (28).
Platelet scintigraphy detects a similar number of mural
thrombi. For example, 48% of patients with anterior in-
farction studied in the first week after infarction had a pos-
itive scan, despite the use of prophylactic subcutaneous
heparin (29).
Embolism. Mural thrombosis, as just described, predis-
poses to embolism, most emboli arising from mural thrombi.
In the 1930s, some 10% of the deaths of patients with
myocardial infarction were attributed to emboli (30). Fur-
thermore, autopsy studies (24,25) reveal emboli in 25 to
50% of cases of myocardial infarction, most commonly to
the viscera. These were likely to be clinically important in
only 5 to 8% of the population studied. In the British Med-
ical Research Council study (31) of anticoagulation in acute
myocardial infarction, 3.4% of the control group (no anti-
coagulation) developed clinical systemic embolism. Em-
bolic stroke occurs in some 2 to 3% of patients within 4
weeks of myocardial infarction, 90% of these strokes oc-
curring in patients with anterior infarction (32,33). The risk
of embolism peaks late in the first week after infarction,
and then decreases rapidly so that after about 6 to 8 weeks,
it is very low (0.35/100 patient-years) (34).
Although riskfactorsfor embolism and mural thrombosis
are similar, clinical prediction of embolism is clearly most
important. Emboli occur most frequently in patients with
echocardiographic evidence of mural thrombus (12,26,35).
JACC Vol. 8, No 6
December 1986:76B-87B
ADAMS ET AL
INTRACARDIAC THROMBOSIS AND EMBOLISM
79B
Mural thrombus is detected most commonly in patients with
a large anterior myocardial infarction and poor hemody-
namic status. Whether the detection of a mural thrombus in
such patients suggests that they are at greater risk of em-
bolism than otherwise similar patients in whom such thrombi
are not detected is at present unknown. However, if a throm-
bus is detected, certain features of the thrombus at echo-
cardiography are associated with a higher rate of embolism.
Protruding thrombi, particularly if they are mobile (13), are
more likely to embolize than are flat thrombi (36,37).
Detection of high risk factors. Other features than those
detected by echocardiography may also be helpful in defin-
ing a group of patients at high risk of embolism. Site of
infarction is important, with emboli being more frequent,
as mentioned, in patients with anterior infarction. However,
in one series (38), 30% of strokes were in patients with
inferior infarctions. Patients with a large infarction are at
higher risk of embolism. In one study (38), nine cases of
stroke occurred in 480 patients receiving no anticoagulants.
All the strokes occurred in patients with a peak creatine
kinase concentration of more than nine times the upper limit
of normal. Venous thromboembolic phenomena were also
confined to this group of patients. Similar findings were
reported by Johannessen et al. (19), who found that patients
developing stroke had a larger heart and higher peak enzyme
concentration than did those without stroke. Another study
(33) failed to confirm these findings, although up to 25%
of the patients with stroke in that series may have had a
nonembolic stroke, and no information is given about ther-
apy. Atrial fibrillation was, however, more common in pa-
tients who developed stroke (33). Plasma fibrinogen con-
centration, which peaks 4 to 6 days after infarction, is also
strongly associated with thromboembolism. In one study
(15) of 120 patients with infarction, all 10 thromboembolic
events recorded (including 4 pulmonary emboli) occurred
in those patients with a fibrinogen concentration greater than
650 mg/dl, with 9 occurring when the concentration was
greater than 800 mg/dl. In that study (15), fibrinogen con-
centration was the best predictor of embolism in a multi-
variate model. It is clear from the foregoing discussion that
patients at high risk of embolism are those with a large
infarction, particularly if anterior, whether or not they have
mural thrombus.
Studies of preventive therapy. The frequency both of
mural thrombus and embolism may be reduced by antico-
agulant therapy, although the two may not be reduced to
the same extent. To be effective in the prevention of mural
thrombus, anticoagulation has to be given in adequate dose
and as early as possible in the course of the condition before
the thrombus has had time to become established. Autopsy
studies (39,40) reveal a reduction in frequency of mural
thrombus of 50 to 70% and an approximate halving in the
rate of systemic embolism with high dose subcutaneous
anticoagulation given soon after arrival in hospital. Mural
thrombus formation and subsequent embolism are not greatly
reduced by low dose or inappropriately timed anticoagu-
lation. This is revealed by the echocardiographic studies
mentioned before, in which patients received anticoagu-
lants, in low doses (that is, heparin subcutaneously 5,000
units twice daily) (12) or the addition of coumadin to initial
low dose heparin only after mural thrombus was detected
(27). However, heparin (to maintain the activated partial
thromboplastin time at 70 to 140 seconds) and warfarin (to
maintain the Thrombotest at 5 to 10%; prothrombin time of
1.4 to 2.2 times control) prevented the development of mural
thrombus in a single-blind study (41), this treatment being
started within 12 hours of the onset of symptoms of infarc-
tion.
Some studies (12,42) suggest that resolution of mural
thrombi is more rapid and complete if anticoagulants are
given. However, another study (43) showed no increase in
the late resolution of mural thrombus with anticoagulants,
despite a definite reduction in the incidence of embolic events.
The differences between the results of the studies on acute
infarction may relate to differences in the groups of patients
studied, in particular, the time at which the echocardiogram
is performed and the time at which the patient enters the
hospital after the onset of symptoms. In summary, the evi-
dence suggests that full anticoagulation when given within
12 hours of the onset of pain moderately reduces the inci-
dence of mural thrombus.
Three large studies (31,44,45) tested whether short-term
anticoagulation can reduce mortality in acute myocardial
infarction and examined the prevention of embolic events
by this therapy. Anticoagulation in these studies consisted
of full dose heparin, either intravenously (31) or subcuta-
neously (44,45), followed by oral anticoagulants to prolong
the prothrombin time to up to 1.5 times control. In the
Medical Research Council (MRC) study (31), for example,
the incidence of systemic emboli during the hospital ad-
mission was reduced by treatment from 3.4% (24 of 715
patients) in the control group to 1.3% (9 of 712 patients)
in the treated group. Overall, the three studies (31,44,45)
suggest a 24 to 75% reduction in relative risk with this
moderate intensity of oral anticoagulation.
Mural thrombosis and systemic embolism may not be
affected by therapy in the same way. Most likely no treat-
ment will prevent the development of minor mural thrombus
due to exposure of damaged tissue. However, further growth
of thrombus with the potential for clinically significant em-
bolism is inhibited by anticoagulants, the rate of embolism
being reduced in the three large trials (31,44,45). Although
the evidence that less intense anticoagulation reduces mural
thrombus formation is contradictory, the evidence is con-
vincing that full dose intravenous heparin followed by oral
vitamin K antagonists protects against embolism.
The risks of anticoagulation in patients with no clear
contraindications were accurately defined by the three large
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studies of acute myocardial infarction (46). In the Veterans
Administration study (44), there were 13 major bleeding
episodes (2.6% of 500 patients) in the treated group and 6
(1.2% of 499) in the untreated group (the anticoagulant agent
was heparin, adjusted according to the clotting time, to-
gether with coumadin until the prothrombin time was greater
than 1.3 times control, then the heparin was discontinued).
In the MRC study (31), clinically obvious hemorrhage was
recorded in 36 (5%) o£112 treated patients and in 9 (1.3%)
of 715 untreated patients. Most of these bleeding episodes
were minor, and no deaths occurred. The risks of short-
term anticoagulation in this group of patients are therefore
low.
The demonstration of mural thrombus on an echocar-
diogram is unlikely to materially alter the decision about
anticoagulation. Anticoagulation has been shown to be ef-
fective if given on admission to hospital, not at other times.
A delay until an echocardiogram is at hand may miss the
time in which therapy can be most valuable. The prevention
of the development of a mural thrombus is the most im-
portant goal of therapy in the acute phase. In one study
(19), warfarin was added to prophylactic heparin only after
a mural thrombus was demonstrated by echocardiography.
Five strokes occurred in the series of 90 patients, and three
were in patients who had been given warfarin after mural
thrombus had been detected (19). Because the majority of
mural thrombi develop only after 3 days after infarction,
echocardiography in the first 2 days would fail to detect the
majority of the patients who would develop mural thrombus
(27). Echocardiography later in the hospital course, for ex-
ample, at 10 days (47), might detect thrombi only after a
significant proportion of the emboli had occurred (33). Mul-
tiple echocardiographic examinations are impractical, ex-
cept as a research tool. Indeed, as discussed, clinical fea-
tures, available in all patients, usefully define a high risk
group.
Suggested management. All patients with a large in-
farction should receive anticoagulants on admission, with
intravenous heparin in full doses. We favor treating patients
who have an anterior infarction or a very extensive inferior
infarction. Although not specifically addressed in this pre-
sentation, the potential for venous thromboembolism is taken
into account when deciding to initiate anticoagulant therapy
in a patient with myocardial infarction. Some risk factors
are common for both arterial and venous thromboembolism,
namely, high peak enzyme concentration, heart failure and
atrial fibrillation.
Oral anticoagulation ofmoderate intensity (prothrombin
time of 1.2 to 1.5 times control, international normalized
ratio of 1.6 to 2.5) should be started 2 to 3 days before
heparin is to be discontinued, and continued for 8 to 12
weeks. Anticoagulation at this intensity is recommended
because it prevented embolism in the MRC and Veterans
Administration studies (31,44). The prevention of ven-
ousthrombosis in patients with acute myocardial infarction
is dealt with elsewhere in this symposium (48,49).
Chronic Left Ventricular Aneurysm
Natural history, epidemiology and risk factors. Vari-
ation in the definition of this condition makes valid com-
parison of various series difficult, particularly because dif-
ferent techniques may be used to define the abnormality
(autopsy, surgery, angiography, echocardiography). How-
ever, there is agreement that mural thrombus within a left
ventricular aneurysm is common. Surgical series (2) have
reported an overall frequency of 47%, with up to 95% in
one series (50). As most of the surgical data are retrospec-
tive, these figures may be underestimated. Necropsy data
(again almost entirely retrospective) (2) suggest a very sim-
ilar (49%) frequency of mural thrombus. The thrombus in
most cases persists from the acute phase of the infarction,
persistence being favored by the stasis within the aneurysm.
Despite the frequent persistence of thrombus, the inci-
dence of clinical systemic embolism gradually decreases
after acute infarction to a low level of 0.35 events per 100
patient-years (34) after about 3 months. The prevalence of
embolism at necropsy in cases of chronic aneurysm is higher
(up to almost 40%) (2). In one study (17) of 100 surgical
cases of chronic aneurysm, five patients had had clinical
emboli, of which four were within 3 months of infarction;
the date of the fifth patient's infarction was unknown. An-
other series (16) of 58 patients described 2 patients with
embolism of which one event occurred despite anticoagu-
lation. In a study in which follow-up and event rate were
carefully documented, Lapeyre et al. (34) described a low
incidence of emboli in a medically managed population with
aneurysm. One event occurred in 288 patient-years of fol-
low-up in 69 patients without anticoagulation (34).
Suggested management. There are no clear data to show
that anticoagulants reduce the rate of embolism in the setting
of chronic left ventricular aneurysm (more than 3 months
after infarction). However, even if there were, because the
rate of embolism is so low in medically managed patients,
the benefits of anticoagulation are unlikely to outweigh the
risks (32,34). If a stroke does occur in a patient with an
aneurysm, it may be due to associated cerebrovascular dis-
ease rather than to an embolus arising from the heart. The
efficacy of anticoagulants in the prevention of recurrent
embolism is not known, but most patients who have had an
embolus would receive anticoagulants.
Occasionally a left ventricular thrombus is discovered at
echocardiography or angiography, most often in a patient
within 6 to 8 weeks of infarction, with features that suggest
that a high risk of embolism is likely. Some investigators
(51) have successfully used urokinase to lyse such a throm-
bus. This approach was successful in the 16 patients in
whom it was attempted, with no embolism in association
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with the treatment. However, embolism was seen in another
group of patients undergoing lysis of thrombus in the left
side of the heart, those with thrombosed left-sided prosthetic
valves (52). The clinical outcome in these cases was good,
despite the embolism. We, therefore, believe that further
experience is necessary before lysis of intracardiac thrombus
can be considered standard therapy. These observations sug-
gest that the use of thrombolytic therapy for patients with
acute infarction will reduce the rate of mural thrombus for-
mation (53). Surgery (thrombectomy or aneurysmectomy)
has been used rarely in patients with large, freely mobile
thrombi or if recurrent embolism has failed to respond to
anticoagulation.
Dilated Cardiomyopathy
Natural history, epidemiology and risk factors. Au-
topsy studies reveal a high incidence of mural thrombi in
patients with dilated cardiomyopathy. For example, Roberts
and Ferrans (II) found intracardiac thrombus in 53% of 60
patients with dilated cardiomyopathy (excluding those with
coronary disease). Thrombi were found in the left ventricle
in 27 cases, in the right ventricle in 15, in the right atrium
in 12 and in the left atrium in 5. In 19 cases, thrombi were
found in more than one chamber. The endocardium under
the thrombus was commonly abnormal. This suggests that
in addition to the slow flow seen in these cases, endocardial
abnormalities predispose to thrombus formation. Indeed, the
preponderance of left ventricular over left atrial thrombus
supports this view because there is a greater degree of stasis
in the atrium, particularly in the appendage.
Clinical studies (54) of patients with dilated cardio-
myopathy suggest that the cumulative incidence of clinical
embolism, secondary in most cases to left ventricular throm-
bus, is 18% in patients not taking anticoagulants. Because
two-thirds of the patients in this Mayo Clinic study died
within 2 years of diagnosis, the rate of embolism was high.
Similar results (15 emboli occurring in 106 patients followed
up to 2 to 22 years) were obtained by Hatle et aI. (55).
There is also a high risk of pulmonary embolism in these
patients, almost 5% in this series (55). Of 100 patients
studied prospectively in another series (56), II had systemic
emboli, while the same number had pulmonary emboli.
Pulmonary embolism, which may contribute to the clinical
condition despite being undiagnosed during life, is frequent
in these patients; thus, the 7% mortality rate due to pul-
monary embolism in this series probably reflects a higher
undiagnosed rate. Embolism in patients with cardio-
myopathy is more frequent than in patients with chronic left
ventricular aneurysms, probably because in the latter, the
wall adjacent to the thrombus is static. There is, therefore,
less stimulus to dislodge the thrombus.
Left ventricular thrombus can be detected noninvasively
in patients with dilated cardiomyopathy as in myocardial
infarction and left ventricular aneurysm. In one series (57),
123 patients with diffuse hypokinesia were studied; in about
60%, this was due to cardiomyopathy and in the remainder
it was due to coronary disease. Thirty-six percent of the
entire group had left ventricular thrombus by echocardi-
ography. Of the 96 patients followed up, 11 % developed
systemic embolism over a mean follow-up period of 21 years
(range 9 months to 4 years; 192 patient-years). The risk of
embolism was not increased in patients with left ventricular
thrombus (40%) by echocardiography. Neither was the cause
of the hypokinesia related to the embolic risk, emboli being
equally frequent in those with coronary disease. The echo-
cardiogram seems unlikely to be useful in defining a high
risk population by the detection of intracardiac thrombus in
patients with cardiomyopathy.
Other factors that determine the risk ofembolism in car-
diomyopathy have been scantily addressed. There are poorly
substantiated suggestions that patients with alcoholic car-
diomyopathy have a particularly high incidence of embo-
lism. A 100% incidence of mural thrombus at postmortem
study has been reported in a well defined group of patients
with alcoholic cardiomyopathy (58). There is a high inci-
dence of embolism in peripartum cardiomyopathy (59) and
in the cardiomyopathy of hypereosinophilia (60). Patients
with hypertrophic cardiomyopathy and atrial fibrillation have
a high incidence of embolism, particularly in association
with rhythm changes (61). In contrast, cardiac rhythm does
not seem to be a major consideration in the majority of
patients with dilated cardiomyopathy, presumably because
the thrombi that are the source of the emboli are usually
ventricular, while in hypertrophic cardiomyopathy, they are
atrial. Fourteen percent of patients with sinus rhythm in one
series (54) of patients with dilated cardiomyopathy devel-
oped emboli, while only 2 of 10 patients developing emboli
in another series (62) had atrial fibrillation. Eight of 15
patients with emboli had sinus rhythm in the series of Hatle
et al. (55). Hemodynamic factors have only rarely been
correlated with the likelihood of embolism in this group of
patients. In one study (57), there was no difference in echo-
cardiographic left ventricular dimensions or ejection fraction
between patients with and without left ventricular thrombus.
Thrombus morphology was not, in this study, associated
with embolic rate.
Suggested management. Little information is available
regarding the role of antithrombotic treatment in the dif-
fusely dilated left ventricle due to ischemic heart disease.
Although there is no prospective study of anticoagulation
in dilated cardiomyopathy, the data from the Mayo Clinic
(54) support the use of anticoagulants in patients with dilated
cardiomyopathy. No patient on anticoagulant therapy de-
veloped a thromboembolic event in 101 patient-years of
follow-up, whereas emboli occurred in 18% of patients not
receiving anticoagulants followed up for 624 patient-years
(that is, an event rate of 3.5/100 patient-years). Although
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the patients were not randomized to the two treatment groups,
the groups were comparable. Thus, it is recommended that
patients with dilated cardiomyopathy receive long-term an-
ticoagulation with coumadin to moderate intensity (32,54).
Furthermore, this is particularly indicated in the presence
of heart failure, prolonged bed rest or other conditions that
predispose to venous thromboembolism, an important ad-
ditional indication for anticoagulant therapy in these pa-
tients. The stage in the natural history of the disorder at
which therapy should be started is not known, but the num-
ber of emboli in the Mayo Clinic study (54) in the first year
after diagnosis suggests that early anticoagulation may be
valuable. The role of antiplatelet agents is unknown. We
see no role for noninvasive detection of thrombi in decision-
making in these patients.
Infective Endocarditis
Thrombosis and the Pathology of Endocarditis
Normal valvular endothelium is resistant to infection.
Trauma to the valve promotes deposition of fibrin and plate-
lets (63), producing the lesion of nonbacterial thrombotic
endocarditis. Experimentally, many forms of stress can
produce nonbacterial thrombotic endocarditis (for example,
severe infections and high cardiac output states). Similar
lesions in all stages of development have been seen in hu-
mans and appear to lead to all cases of infective endocarditis
(64). The same pathologic findings are seen in marantic
endocarditis without infection (for example, with some ma-
lignancies and connective tissue disorders).
In experimental animals, treatment with anticoagulants
(65), aspirin (66) and sulfinpyrazone (67) has been used in
an attempt to reduce the deposition of platelets and fibrin
during the induction of endocarditis. Although vegetation
size was reduced by sulfinpyrazone in one study (67) of
sterile vegetations, aspirin in large doses had no effect in
another study (66). Survival of rabbits with experimental
infective endocarditis was reduced by warfarin (65), even
in the presence of penicillin. There are no data regarding
the effect of antiplatelet agents or anticoagulants on the
prevention of endocarditis in human subjects (63).
Embolism in Endocarditis
Natural history, epidemiology and risk factors. Sys-
temic embolism, including to the brain, is the major com-
plication of endocarditis after congestive failure. Cerebral
embolism with stroke occurs in 6 to 31 % of cases treated
currently (68), in 17% in one large series from the Mas-
sachusetts General Hospital (69). Strokes occur most com-
monly in the territory of the middle cerebral artery. Mi-
croemboli to the cerebral circulation are also common;
sometimes silent, they may lead to confused mental states
or mood changes. Emboli to other organs may not be clin-
ically apparent; autopsy data revealed splenic and renal em-
boli in 44 and 56% of patients, respectively (70). Coronary
emboli with small areas of myocardial infarction may occur
in up to 40 to 60% of autopsy cases (64). Pulmonary emboli
are common in right-sided endocarditis. Although these phe-
nomena are common, emboli occluding large vessels like
the femoral artery are uncommon, and are more usually due
to fungal or marantic endocarditis. Left atrial myxoma may
also embolize to large peripheral arteries. Emboli remain
an important cause of death in endocarditis, causing 16%
of the deaths in one series (71) performed in the early 1970s.
Emboli occasionally occur despite successful antibiotic ther-
apy, even long after the illness.
Emboli occurring in the early phase of the illness are
most likely to be in the context of Staphylococcus aureus
infection (69,71). The slower growing but less common
fungi (Aspergillus and Candida) and the carbon dioxide-
requiring bacteria (Hemophilus spp., Cardiobacterium hom-
inis and Actinobacillus) produce large vegetations with a
high risk of embolism (68). In the later phase of the illness,
streptococcol infection accounts for almost half of the cases
of embolism.
Some studies (69) find that mitral valve injections lead
to embolism more commonly than do aortic value injections,
while others (71) reach the opposite conclusion. Overall, it
seems likely that aortic valve involvement leads to emboli
more frequently (72). The reported rate of recurrence of
emboli is variable; in the Massachusetts General Hospital
series (69), only I of 37 patients had a second major cerebral
embolus. However, 47% of patients with cerebral embolism
had systemic embolism, and almost 30% of patients with
stroke (both embolic and hemorrhagic) had a premonitory
transient ischemic attack. Also, recent unpublished retro-
spective data from our institution (72) in a group of patients
with echocardiographically detected vegetations show that
the rate of recurrent emboli is twice that of first emboli.
This opinion is not universal: to quote a recent review (73),
"there are no data to suggest that a patient with one or two
major emboli is at increased risk of having more... " De-
spite these reservations, we believe that the occurrence of
one embolic event does presage a further event. Finally,
there is little doubt that patients with mechanical prosthetic
valve endocarditis have a high rate of embolism, particularly
if anticoagulant treatment has been discontinued for some
reason (74).
Patients in whom vegetations are detected by echocardi-
ography are at higher risk oj embolism than are those in
whom they are not detected. A recent review (75) sum-
marized the findings in 442 patients from several studies.
Thirty-four percent of patients with vegetations on echo-
cardiography had systemic embolism, whereas this occurred
in only 7% of patients without vegetations. Other workers
(76,77) have shown that patients with large vegetations are
more likely to develop a first embolism than are those with
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small vegetations (0,1 em). Similar observations have been
made in our institution (72); patients with vegetations of an
area greater than 1.8 cm2 as judged by two-dimensional
echocardiography were more than 2.5 times more likely to
have emboli than were those with smaller vegetations. Fur-
thermore, in one study (78), multiple emboli occurred in
patients with large vegetations. Although the echocardio-
graphic detection of vegetations defines a population with
a high incidence of embolic events, the predictive value in
the individual is not high; in general, 50 to 75% of patients
have echocardiographic vegetations, whereas only about 33%
will have clinically apparent emboli. The detection of large
vegetations may be of greater predictive value.
Can anticoagulant therapy prevent embolism in na-
tive valve infective endocarditis without excessive risk?
The role of anticoagulants in native valve infective endo-
carditis is controversiaL with contradictory opinions being
expressed in the literature. Portions of established vegeta-
tions may embolize despite adequate anticoagulation, An
alternative view is that anticoagulants could prevent layering
and extension of additional friable thrombus, Clinical stud-
ies have not provided an answer. One author states: "An-
ticoagulants do not prevent emboli in infective endocardi-
tis" (79). For example, in the Massachusetts General Hospital
series (69), a subset of seven patients were treated with
anticoagulants and yet five experienced embolism. In con-
trast, other investigators (32) clearly believe that antico-
agulants are effective, There are no data regarding the use
of antiplatelet agents in this setting,
Although the possible benefits of anticoagulation are un-
clear, the risk of cerebral hemorrhage in patients with in-
fective endocarditis is certainly high, In the early 1940s,
heparin was used in the treatment of patients with endo-
carditis in an attempt to improve penicillin penetration into
vegetations (80), However an unacceptably high rate (at
least 20%) of cerebral hemorrhage occurred (81), after only
short courses of heparin. Warfarin therapy shortens survival
in experimental endocarditis in rabbits (65), In the Mas-
sachusetts General Hospital series (69), three of seven pa-
tients receiving anticoagulants developed hemorrhagic cere-
bral infarction. Cerebral hemorrhage occurred in only 10 of
211 patients not receiving anticoagulants,
Anticoagulation increases the likelihood ofcerebral hem-
orrhage in endocarditis. which may be due to bleeding from
mycotic aneurysms hemorrhagic transformation of embolic
infarction or subarachnoid or intracerebral hemorrhage with
no identifiable cau~e. Mycotic aneurysms are detected in
life in a small percent of patients (69,70) and in up to 10%
at autopsy, Because these aneurysms may resolve sponta-
neously, the true incidence is unknown. Such aneurysms
commonly arise after septic emboli to the vessel wall. Per-
haps 50% of patients with a mycotic aneurysm will have
had preceding cerebral signs or symptoms. Certainly, the
absence of neurologic manifestations reduces the likelihood
of a mycotic aneurysm. In summary, the diagnosis of a
mycotic aneurysm is a very strong contraindiction to anti-
coagulation (32). Thus, in a patient in whom anticoagulation
is necessary (for example for cardiopulmonary bypass), full
neurologic evaluation including angiography should be con-
sidered, particularly in the presence of prior neurologic man-
ifestations.
Anticoagulants in prosthetic valve endocarditis. It
would seem appropriate not to institute prophylactic anti-
coagulation in patients with endocarditis on a bioprosthetic
valve, although continuing established antithrombotic ther-
apy is a reasonable policy. To our knowledge, there is little
information regarding these issues. Several studies have
addressed the matter of continuing anticoagulants in patients
with mechanical prosthetic valve endocarditis. A retrospec-
tive study from the Mayo Clinic (74) strongly supports con-
tinuing anticoagulants in these patients; stroke occurred in
3 (8%) of 38 patients on anticoagulant therapy and in 10
(71 %) of 14 patients in whom anticoagulants were with-
drawn or were at doses producing inadequate anticoagula-
tion. Other studies (82,83) report a high incidence of neu-
rologic complications despite anticoagulation. For example,
one study (82) reports that 10 (24%) of 42 patients on
anticoagulant therapy experienced embolic (four patients)
or hemorrhagic (six patients) events. In each study, hem-
orrhage was associated particularly, but not exclusively,
with excessive anticoagulation. Although anticoagulants
should be continued in the setting of prosthetic endocarditis,
it has to be accepted that the risk of both embolic and
hemorrhagic events remains high.
Suggested management. In native valve endocarditis,
there is no evidence for efficacy, whereas there is certainty
that anticoagulant treatment increases the risk of hemor-
rhage. Therefore, anticoagulation is not recommended to
prevent emboli, Neither is there good evidence that anti-
coagulation reduces the risk of recurrent embolism once an
initial event has occurred. If anticoagulation becomes nec-
essary (for example, if cardiopulmonary bypass is needed),
consideration should be given to the possibility of a mycotic
aneurysm. In mechanical prosthetic valve endocarditis, an-
ticoagulation should be discontinued temporarily if cerebral
embolism does occur. Care should be taken to minimize the
likelihood of excessive anticoagulation. Bioprosthetic valve
endocarditis should be treated in the same way as infection
on a native valve, with previous antithrombotic therapy
being continued. Again, care has to be taken to avoid ex-
cessive anticoagulation.
Atrial Fibrillation
Natural history, epidemiology and risk factors. As
discussed elsewhere in this symposium (84) patients with
atrial fibrillation and valvular heart disease have a high rate
of embolism. However, nonvalvular atrial fibrillation occurs
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much more commonly and is numerically a more important
potential cause of embolism.
Atrial fibrillation is a relatively common arrhythmia, oc-
curring in 2 to 3 people per 1,000 from ages 25 to 34 years
and 30 to 40 per 1,000 from ages 55 to 64 years in the
Framingham Study (85). In people aged 62 to 90 years in
Edinburgh, Scotland, the rate was 50 to 90 per 1,000 (86).
In an earlier report (87) from the Framingham Study, the
risk of stroke in nonvalvular atrial fibrillation was 41.8 per
1,000 patient-years, a relative risk of 5.6 (87). An overall
annual stroke risk in nonvalvular atrial fibrillation of 3 to
5% has been suggested (32), with a 35% cumulative lifetime
incidence. Nonvalvular atrial fibrillation is found in 45% of
patients with cardiac embolic strokes, accounting for 5 to
6% of all strokes (32). Of course, many of the patients with
nonvalvular atrial fibrillation have other associated cardiac
conditions (for example, hypertensive or ischemic heart dis-
ease). They, therefore, differfrom the patients with "lone"
atrial fibrillation.
Thrombus formation in the left atrium in nonvalvular
atrial fibrillation is likely related to stasis, but the role of
additional endocardial abnormalities has not been addressed.
The best predictor of stroke in patients with nonvalvular
atrial fibrillation is a first stroke since recurrence occurs in
up to 10 to 20% patients per annum (32). The rate of em-
bolism is partly determined by the etiology of the arrhyth-
mia. In patients with coronary disease, the incidence of
clinical embolism is relatively low. However, because coro-
nary disease is so common, it is a frequent cause of atrial
fibrillation and embolism. Subclinical emboli, often of un-
certain clinical significance, are common at autopsy in these
patients. In one autopsy series (88), 35% of patients with
atrial fibrillation due to ischemic heart disease had systemic
emboli, while only 7% of a control group with ischemic
heart disease and sinus rhythm had emboli; in most patients,
embolization involved the brain (73%). Many patients with
coronary disease and atrial fibrillation, who are at an in-
creased risk of embolism, also have other relative indica-
tions for anticoagulation (for example, congestive failure
with its high risk of pulmonary embolism). Patients with
cardiomyopathy have already been dealt with. Patients
younger than 65 years of age with lone atrial fibrillation
(with no other detectable heart disease) have a low incidence
of embolism; 94% of 98 patients were free of embolic events
at 10 years in a study from the Mayo Clinic (89). The rate
is much higher in older patients with the bradycardia-tachy-
cardia syndrome. Thus, in one study (90) of 100 such pa-
tients, 16 had had systemic embolism during a median pe-
riod of 4 years (range of a to 50). In this study, other risk
factors included age greater than 50 years and prolonged
atrial asystole, emphasizing the effect of stasis on thrombus
formation in the left atrium. Atrial fibrillation occurs in
congenital heart disease, but the risk of stroke is not well
documented. A high incidence of embolism was reported
by Forfang et al. (91) in secundum atrial defect with atrial
fibrillation. Thyrotoxic atrial fibrillation is associated with
a high risk of embolism (8 to 39%, average 14). In one
series (92), 12 of 30 patients with thyrotoxic atrial fibril-
lation developed emboli, 53% of which were cerebral; as
only 4 patients were in chronic atrial fibrillation, the rate
of embolism was very high.
Stability of cardiac rhythm and left atrial size have not
been clearly related to the risk of embolism in nonvalvular
atrial fibrillation. Detection of left atrial thrombus by echo-
cardiography is unreliable, and by other modalities (for ex-
ample, computed tomography) is not established. In patients
with atrial fibrillation, recurrent stroke after an initial event
is common, occurring in up to 10 to 20% per year (32).
Thus, the best predictor of stroke in these patients is an
initial event.
Role of anticoagulation. The first stroke in patients with
nonvalvular atrial fibrillation is likely to be clinically very
significant. Therefore, prevention of stroke in these patients
is important. There are no data regarding the use of anti-
platelet agents in this context. Anticoagulation has been used
frequently, but there are no good controlled studies. How-
ever, it is likely that they are efficacious, by analogy with
their efficacy in valvular heart disease, and in the prevention
of embolism in acute myocardial infarction.
In a comparative study with historic controls, Freeman
and Wexler (93) showed a reduction in the rate of throm-
boembolism in patients with" arteriosclerotic" heart disease
and atrial fibrillation from 4.9% in untreated patients to
0.6% in patients receiving anticoagulants, with a similar
reduction in embolism detected at autopsy. A careful anal-
ysis of the risks and benefits of anticoagulation in the brady-
cardia-tachycardia syndrome (94) suggests that anticoagu-
lation is beneficial in this condition, even when the
assumptions made were generally unfavorable to antico-
agulation.
Suggested management. Prevention of recurrent em-
bolism should be considered in each of the patient groups
discussed here by long-term moderate intensity anticoagu-
lation (prothrombin time with rabbit thromboplastin 1.2 to
1.5 times control). This recommendation is based on anal-
ogy with venous thromboembolism, in which stasis prob-
ably plays a similar pathologic role, and against which mod-
erate intensity oral anticoagulation provides effective
prophylaxis (32). However, because many of the patients
with nonvalvular atrial fibrillation are elderly, careful con-
sideration of the potential risks and benefits in the individual
is crucial. Aspirin might well be considered in some cases,
although in the absence of evidence for its efficacy.
Anticoagulation for cardioversion for atrial fibrilla-
tion. Several studies document the risk of embolism after
cardioversion for atrial fibrillation (reviewed by Mancini
and Goldberger [95]) as being 1 to 3%, the highest figure
of 5.3% being found in a comparative study (96) in which
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embolism occurred in 0.8% of patients on anticoagulant
therapy. Although this risk may seem low, it is a much
higher rate per patient-year than for most other considera-
tions. This comparative study suggests that long-term an-
ticoagulation before cardioversion reduces the risk of em-
bolism. However, the issue is one of administering short-
term anticoagulation before cardioversion in patients who
would otherwise not be given an anticoagulant. There are
no data regarding the rate of development of intraatrial
thrombus or the time needed for it to become adherent to
the atrial wall once present. A 2 week period is assumed
to be needed (97) and, therefore, 2 to 3 weeks of moderate
intensity anticoagulation is recommended to allow thrombus
to become adherent before cardioversion. This should be
continued for about 3 to 4 weeks thereafter because atrial
mechanical activity may take 3 to 4 weeks to resume despite
electrical sinus rhythm (98). Indeed, the cardiac condition
predisposing to atrial fibrillation will, in many patients,
warrant long-term anticoagulation.
Whether all patients should receive an anticoagulant be-
fore cardioversion is unknown. The risk of embolism is
higher in patients with cardiac conditions that in themselves
produce a significant risk of embolism and in whom long-
term anticoagulation would be considered. In lower risk
patients (for example, those with ischemic heart disease),
some authorities would use aspirin given for 2 to 3 weeks
before cardioversion.
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